RxDoctor Payments Data

Angela Spraggins

Family · Rio Rancho, NMNPI 1366180994

Payments from drug & device makers

$1,077in general payments, 2019–2025

Across 29 payments — averaging $37.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$346
  • Otsuka America Pharmaceutical, Inc.$169
  • GSK$142
  • Phathom Pharmaceuticals, Inc.$104
  • Exact Sciences$81
  • Novo Nordisk$73
  • plus $162 from 4 others

What the payments were for

  • Food & beverage$1,077100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,077 in reported general payments places this provider in the 80th percentile of 1,080 family providers in New Mexico.

See all family providers in New Mexico

Medicare billing

Part B allowed, 2024
$30,422
Medicare patients
166
Services billed
366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide61$86,676
TrulicityDulaglutide33$36,097
OzempicSemaglutide18$20,882
EliquisApixaban13$16,474
JardianceEmpagliflozin13$12,071
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/723$11,342
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$3,679
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$3,619
Advair HfaFluticasone Propion/Salmeterol13$3,401
Atorvastatin Calcium247$2,903
Albuterol Sulfate HfaAlbuterol Sulfate106$2,765
Levothyroxine Sodium228$2,761
ShingrixVaricella-Zoster Ge/As01b/Pf11$2,345
Gabapentin107$2,094
Arnuity ElliptaFluticasone Furoate11$2,012

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$346$122,77394 claims
Novo NordiskOzempic$73$20,88218 claims
PfizerEliquis$62$16,47413 claims
GSKShingrix, Arnuity Ellipta$142$4,35722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,080 family providers in New Mexico.

Other family in Rio Rancho

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →